-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Dyne reports heart and lung function improvements in DMD trial
-
-
-
-
-
-
-
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform
-
-
-
-
-
-
-
Bernstein sees favorable risk-reward in this biotech stock
-
-
-
-
-
-
-
Piper Sandler: 'Own Dyne Therapeutics (DYN) for DELIVER Data in Late 2025'
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $11.50 at Bernstein
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
418,725 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

